Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.05
0% from low
Exchange
OTC Link
CS
ARIDIS PHARMACEUTICAL INC
No one on the platform currently holds ARDS.
No tracked institution reports a position in ARDS as of their last filing.
No one on the platform has traded ARDS yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
@BuyoutBobby Are you predicting another buyout like how you did with $ARDS? @ChiefStockTraderJr
View on StockTwits ↗$ARDS That is @BuyoutBobby you are referring to. One minute he claimed he was going to travel from Deustchland and file a lawsuit against ARDS for choosing to delist from the markets. Then he said a buyout was imminent because he had "insider informations", and he was going to ten times his Deustche Marks investment and become a bazillionaire. But he has mostly dropped the bravado and seems to have sold all his ARDS shares.
View on StockTwits ↗$ARDS There was a guy who used to post here for years, talking about he was going to go after the CEO for this and that. I wonder what ever became of him or how successful he was. As far as I can tell, the company is still worth zero just like our investments.
View on StockTwits ↗$ARDS Even @BuyoutBobby thinks this one is completely dead. Vu can't even find a merger partner, or do a buyout to some other small biotech.
View on StockTwits ↗Fundamental analysis of $ARDS (Aridis Pharmaceuticals, Inc.) based on financial data and reported results. #ARDS #Aridis
View on StockTwits ↗$ARDS I wouldn't pay any attention to Buyout Bobby. Buyout Bobby thinks he has me blocked. Buyout Bobby wrote: "those articles don't mean much. They are published all the time." This is the first article posted on ARDS in a long, long time.
View on StockTwits ↗$ARDS Check the date at the bottom of this filing: https://www.sec.gov/Archives/edgar/data/1614067/000117266126002121/xslSCHEDULE_13G_X02/primary_doc.xml
View on StockTwits ↗$ARDS https://finance.yahoo.com/sectors/healthcare/articles/pneumonia-market-set-witness-robust-140100395.html
View on StockTwits ↗$ARDS if you plan to sue, the window is closing: Filing a Civil Lawsuit (Securities Fraud) If you believe the company or its executives misled investors and you are looking to join or initiate a civil lawsuit to recover funds, the legal windows are much tighter. The 2-Year / 5-Year Rule: Under the Securities Exchange Act, civil lawsuits for securities fraud must be filed within 2 years after you discover the facts constituting the violation. The Statute of Repose: There is a hard legal cap of 5 years after the actual violation occurred, regardless of when you discovered the fraud. Once that 5-year mark hits, the liability is extinguished. Criminal Prosecution: For context, if the federal government (DOJ) pursues the company, they have a 6-year statute of limitations to bring criminal securities fraud charges.
View on StockTwits ↗$ARDS Anything new? Like an old ghost town around here. I can almost hear the squeaking doors moving in the wind. It sure blew away our money like tumbleweeds. Nothing left but a lonely empty shell now. Shoulda been. Coulda been. Woulda been. Hey, let's not kid ourselves, we were robbed like a Jessie James holdup. Make no bones about it.
View on StockTwits ↗$ARDS If the state filing is delinquent., the shareholders can takeover the company under state law and bring the OTC listing to full compliance.
View on StockTwits ↗$ARDS My smallest checking account has more money than the entire market cap of this stock. Who works there? Volunteers?
View on StockTwits ↗$ARDS I was really disappointed on how this stock played out. I expected it to be some short gold mine or something. A diamond in the rough. It turned out to be just a hard road apple.
View on StockTwits ↗$ARDS they published a news on their website. Maybe its not over yet.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $111M | +66.3% | $3.30 | $3.30–$3.30 | 0.0× | 1 |
| 2027 | $171M | +54.8% | $5.43 | $5.43–$5.43 | 0.0× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2023-11-03 | $-0.10 | $-0.02 | +80.0% |
| 2023-06-08 | $-0.41 | $-0.22 | +46.3% |
| 2023-04-28 | $-0.41 | $-0.35 | +14.6% |
| 2022-11-21 | $-0.17 | $-0.47 | -176.5% |
| 2022-08-16 | $-0.06 | $-0.45 | -650.0% |
| 2022-05-16 | $-0.51 | $-0.44 | +13.7% |
| 2022-03-31 | $-0.41 | $-0.92 | -124.4% |
| $92M |
| — |
| ICCTiCoreConnect Inc. | $0.00 | +0.00% | $5365 | — |
| INFIQInfinity Pharmaceuticals, Inc. | $0.00 | +0.00% | $9076 | — |
Source: Financial Modeling Prep · peers by sector/industry